AbCellera Biologics Inc. ABCL
AbCellera Biologics Inc. (Nasdaq: ABCL) is an endocrine/women's health drug developer. Its lead program, ABCL635, is in Phase 2 for Moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Its next catalyst on record is ABCL575: Phase 1 topline data readout (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ABCL575 — Phase 1 topline data readout (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ABCL635 | Menopausal vasomotor symptoms (NK3R antagonist) | antibody | Phase 2 |
| ABCL575 | Atopic dermatitis (OX40L) | antibody | Phase 1 |
| ABCL688 | Autoimmunity (undisclosed GPCR/ion channel target) | antibody | Pre-clinical |
| ABCL386 | Oncology (undisclosed target) | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.